Pharmaceutical foam compositions substantially free of ethanol and comprising pimecrolimus in a carrier vehicle comprising a mixture of oily solvents amounting to at least 40% of the total weight of the composition and consisting of: i) hexylene glycol； ii) optionally oleyl alcohol； and iii) dimethylisosorbide and/or medium chain triglycerides； and additionally: iv) when oleyl alcohol is absent, water in an amount of less than 25%； v) at least one consistency agent； vi) at least one preservative； and vii) at least one surfactant/emulgator； and propellant gas for foaming； and optionally further conventional excipients. They are indicated for use in the treatment of various skin, nail and mucosal diseases.
